Inhibrx Inc INBX

NAS: INBX | ISIN: US45720L1070 1/05/2025

12,32 USD (-0,08%)

(-0,08%) 1/05/2025

Grafiek Inhibrx Inc

Grafiek Inhibrx Inc

1 dag1d -0,08%
1 week1w 0,49%
1 maand1m -12,62%
3 maanden3m -3,14%
6 maanden6m -20,77%
1 jaar1j -63,78%
5 jaar5j -40,28%

Inhibrx Inc in het nieuws

Toon enkel gratis nieuws

1 april 2025 · Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President · Persbericht

17 maart 2025 · Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results · Persbericht

14 augustus 2024 · Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights · Persbericht

24 mei 2024 · Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi · Persbericht

11 mei 2024 · Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off · Persbericht

8 mei 2024 · Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger · Persbericht

27 maart 2024 · TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX · Persbericht

12 maart 2024 · INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN · Persbericht

28 februari 2024 · Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results · Persbericht

23 januari 2024 · Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B · Persbericht

Profiel Inhibrx Inc

Gezondheidstechnologie

Website: inhibrx.com

Hoofdzetel: La Jolla, California Verenigde Staten

CEO: Mark Paul Lappe

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe